Pomaglumetad methionil: Phase IIb data

The double-blind, international, pivotal Phase IIb H8Y-MC-HBBM trial in about 1,000 patients with acute schizophrenia showed that twice-daily 40 and 80 mg oral pomaglumetad methionil as monotherapy for up to 7 weeks each missed the co-primary endpoints of improving PANSS total score from baseline vs. placebo in the overall population and in an undisclosed predefined genetic subgroup of schizophrenia patients. Eli Lilly said that the active control risperidone did meet the co-primary endpoints vs. placebo. Pomaglumetad methionil was generally well tolerated. ...